CHST13抑制肝癌细胞侵袭能力的研究

doi:10.3760/cma.j.issn.1673422X.2014.04.022

摘要/Abstract

摘要： 目的通过研究磺基转移酶CHST13在人肝癌高转移细胞株MHCC97H和人肝癌低转移细胞株MHCC97L中的差异表达，明确其与肝癌转移的相关性，从而证实肝癌转移诊断及抗肿瘤治疗新靶点。方法采用实时PCR、Western blot分析磺基转移酶CHST13在人肝癌高、低转移细胞株的差异表达，通过RNA干扰技术干预CHST13基因，检测干扰前后MHCC97L细胞的体外侵袭力及体内成瘤性。结果CHST13在人肝癌高、低转移细胞株中表达具有明显差异；下调MHCC97L细胞中CHST13基因表达后，穿过基底膜的细胞数量［（30±3）个］明显多于未处理组［（14±2）个］，体外侵袭力显著增强(t=2.8，P=0.005)；相对于正常细胞［（0.5±0.06） g］，干扰后细胞的肿瘤平均重量［（0.9±0.10）g］明显增大，体内成瘤性明显提高（t=2.5，P=0.01）。结论磺基转移酶CHST13与肝癌细胞的侵袭、成瘤性密切相关，其有望成为肝癌临床治疗的新靶点。

关键词: 磺基转移酶类, 癌, 肝细胞, 肿瘤转移

Abstract: ObjectiveTo clarify the association between chondroitin4Osulfotransferase3 (CHST13) and hepatoma metastasis by the research of differential expression of CHST13 in MHCC97H and MHCC97L human hepatocarcinoma cell lines, which have high and low metastatic potential, respectively, and to confirm novel target of hepatoma metastasis and antitumor therapy. MethodsThe differential expressions of CHST13 in MHCC97H and MHCC97L human hepatocarcinoma cell lines were analyzed by realtime PCR, Western blot. CHST13 was silenced using RNA interference approach to detect the invasive ability in vitro and tumorigenicity in vivo in MHCC97L cells. ResultsThe expression of CHST13 was different in MHCC97L cells, as compared to those in MHCC97H cells. Knockdown of CHST13 expression enhanced MHCC97L cells invasion and tumorigenicity both in vitro (t=2.8, P=0.005) and in vivo (t=2.5, P=0.01). The quantity of cells which crossed basement membrane increased ［(30±3)∶(14±2)］, and the average weight of tumor increased ［(0.9±0.10) g∶(0.5±0.06) g］. ConclusionThe differential expressions of CHST13 in human hepatocarcinoma cell lines correlate with tumor invasion and tumorigenicity, and it is expected to be a novel target for the treatment of hepatocellular carcinoma.

Key words: Sulfotransferases, Carcinoma, hepatocellular, Neoplasm metastasis

李艳平, 刘有训, 马红叶, 王宁, 张旭. CHST13抑制肝癌细胞侵袭能力的研究[J]. 国际肿瘤学杂志, 2014, 41(4): 314-318.

LI Yan-Ping, LIU You-Xun, MA Hong-Ye, WANG Ning, ZHANG Xu. CHST13 inhibits the invasive property of human hepatocellular carcinoma cells[J]. Journal of International Oncology, 2014, 41(4): 314-318.

参考文献

［1］ Mantelli F, Schaffer L, Dana R, et al. Glycogene expression in conjunctiva of patients with dry eye: downregulation of Notch signaling［J］. Invest Ophthalmol Vis Sci, 2009, 50(6): 26662672. ［2］ Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease［J］. Cell, 2006, 126(5): 855867. ［3］ Guo R, Cheng L, Zhao Y. Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells［J］. Int J Biochem Cell Biol, 2013, 45(2): 347358. ［4］ Kang HG, Evers MR, Xia G, et al. Molecular cloning and characterization of chondroitin4Osulfotransferase3. A novel member of the HNK1 family of sulfotransferases［J］. J Biol Chem, 2002, 277(38): 3476634772. ［5］ Gu J, Taniguchi N. Potential of Nglycan in cell adhesion and migration as either a positive or negative regulator［J］. Cell Adh Migr, 2008, 2(4): 243245. ［6］ Dove A. The bittersweet promise of glycobiology［J］. Nat Biotechnol, 2001, 19(10): 913917. ［7］ Haltiwanger RS, Lowe JB. Role of glycosylation in development［J］. Annu Rev Biochem, 2004, 73: 491537. ［8］ Bertozzi CR, Kiessling LL. Chemical glycobiology［J］. Science, 2001, 291(5512): 23572364. ［9］ Klüppel M, SamavarchiTehrani P, Liu K, et al. C4ST1/CHST11controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome［J］. Eur J Hum Genet, 2012, 20(8): 870877. ［10］ Klüppel M. The roles of chondroitin4sulfotransferase1 in development and disease［J］. Prog Mol Biol Transl Sci, 2010, 93: 113132. ［11］ Yin X, Truty J, Lawrence R, et al. A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis［J］. Mol Cancer, 2010, 9: 316. ［12］ Cooney CA, Jousheghany F, YaoBorengasser A, et al. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface Pselectin ligands in aggressive breast cancer cells［J］. Breast Cancer Res, 2011, 13(3): R58. ［13］ Yang JD, Sun Z, Hu C, et al. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival［J］. Genes Chromosomes Cancer, 2011, 50(2): 122135.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.